Cargando…

Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures

OBJECTIVE: Among standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one‐half of the patients. To establish precision medicine, we examined pharmacoresistance of focal epileptic spasms (ES), generalized ES, and ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Yukitoshi, Ota, Akiko, Tohyama, Jun, Kirino, Tomoko, Fujiwara, Yumi, Ikeda, Chizuru, Tanaka, Shigeki, Takahashi, Jyunya, Shinoki, Toshihiko, Shiraga, Hiroshi, Inoue, Takushi, Fujita, Hiroshi, Bonno, Motoki, Nagao, Masayoshi, Kaneko, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886099/
https://www.ncbi.nlm.nih.gov/pubmed/34773678
http://dx.doi.org/10.1002/epi4.12560
_version_ 1784660576750796800
author Takahashi, Yukitoshi
Ota, Akiko
Tohyama, Jun
Kirino, Tomoko
Fujiwara, Yumi
Ikeda, Chizuru
Tanaka, Shigeki
Takahashi, Jyunya
Shinoki, Toshihiko
Shiraga, Hiroshi
Inoue, Takushi
Fujita, Hiroshi
Bonno, Motoki
Nagao, Masayoshi
Kaneko, Hideo
author_facet Takahashi, Yukitoshi
Ota, Akiko
Tohyama, Jun
Kirino, Tomoko
Fujiwara, Yumi
Ikeda, Chizuru
Tanaka, Shigeki
Takahashi, Jyunya
Shinoki, Toshihiko
Shiraga, Hiroshi
Inoue, Takushi
Fujita, Hiroshi
Bonno, Motoki
Nagao, Masayoshi
Kaneko, Hideo
author_sort Takahashi, Yukitoshi
collection PubMed
description OBJECTIVE: Among standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one‐half of the patients. To establish precision medicine, we examined pharmacoresistance of focal epileptic spasms (ES), generalized ES, and generalized ES combined with focal seizures, diagnosed based on the revised seizure classification of ILAE in 2017. METHODS: We conducted a retrospective nationwide study in Japan on the long‐term seizure outcome of ES. Long‐term seizure outcome was evaluated by seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve. Seizure‐free was defined as seizure control for longer than 2 months. RESULTS: From the medical history of 501 patients, 325 patients had generalized ES only (GES group) at the start of the first treatment, 125 patients had generalized ES after focal seizure onset (FS‐GES group), seven patients had focal ES after focal seizure onset (FS‐FES group), and 24 patients had generalized ES combined with focal seizures after focal seizure onset (FS‐GES + FS group). Seizure‐free period of ES (generalized ES and focal ES) [mean (95% confidence interval)] was 2.7 (0.0‐5.4) months in GES group, 1.1 (0.1‐2.2) months in FS‐GES group, 1.0 (0.2‐1.9) months in FS‐GES + FS group, and 0.1 (−0.2‐0.5) months in FS‐FES group. Seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve of generalized ES were almost the same in GES group and FS‐GES group, with characteristics of superior response to ACTH. Mean seizure‐free period of generalized ES combined with focal seizures was significantly shorter in FS‐GES + FS group than in GES group. Mean seizure‐free period of focal ES in FS‐FES group was extremely short with exceedingly early relapse. SIGNIFICANCE: Pharmacoresistance was different in generalized ES, focal ES, and generalized ES combined with focal seizures. ES with focal features or with focal seizures may have focal lesions, thus consider surgical options earlier in the course.
format Online
Article
Text
id pubmed-8886099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88860992022-03-04 Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures Takahashi, Yukitoshi Ota, Akiko Tohyama, Jun Kirino, Tomoko Fujiwara, Yumi Ikeda, Chizuru Tanaka, Shigeki Takahashi, Jyunya Shinoki, Toshihiko Shiraga, Hiroshi Inoue, Takushi Fujita, Hiroshi Bonno, Motoki Nagao, Masayoshi Kaneko, Hideo Epilepsia Open Original Articles OBJECTIVE: Among standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one‐half of the patients. To establish precision medicine, we examined pharmacoresistance of focal epileptic spasms (ES), generalized ES, and generalized ES combined with focal seizures, diagnosed based on the revised seizure classification of ILAE in 2017. METHODS: We conducted a retrospective nationwide study in Japan on the long‐term seizure outcome of ES. Long‐term seizure outcome was evaluated by seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve. Seizure‐free was defined as seizure control for longer than 2 months. RESULTS: From the medical history of 501 patients, 325 patients had generalized ES only (GES group) at the start of the first treatment, 125 patients had generalized ES after focal seizure onset (FS‐GES group), seven patients had focal ES after focal seizure onset (FS‐FES group), and 24 patients had generalized ES combined with focal seizures after focal seizure onset (FS‐GES + FS group). Seizure‐free period of ES (generalized ES and focal ES) [mean (95% confidence interval)] was 2.7 (0.0‐5.4) months in GES group, 1.1 (0.1‐2.2) months in FS‐GES group, 1.0 (0.2‐1.9) months in FS‐GES + FS group, and 0.1 (−0.2‐0.5) months in FS‐FES group. Seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve of generalized ES were almost the same in GES group and FS‐GES group, with characteristics of superior response to ACTH. Mean seizure‐free period of generalized ES combined with focal seizures was significantly shorter in FS‐GES + FS group than in GES group. Mean seizure‐free period of focal ES in FS‐FES group was extremely short with exceedingly early relapse. SIGNIFICANCE: Pharmacoresistance was different in generalized ES, focal ES, and generalized ES combined with focal seizures. ES with focal features or with focal seizures may have focal lesions, thus consider surgical options earlier in the course. John Wiley and Sons Inc. 2021-11-19 /pmc/articles/PMC8886099/ /pubmed/34773678 http://dx.doi.org/10.1002/epi4.12560 Text en © 2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Takahashi, Yukitoshi
Ota, Akiko
Tohyama, Jun
Kirino, Tomoko
Fujiwara, Yumi
Ikeda, Chizuru
Tanaka, Shigeki
Takahashi, Jyunya
Shinoki, Toshihiko
Shiraga, Hiroshi
Inoue, Takushi
Fujita, Hiroshi
Bonno, Motoki
Nagao, Masayoshi
Kaneko, Hideo
Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
title Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
title_full Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
title_fullStr Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
title_full_unstemmed Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
title_short Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
title_sort different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886099/
https://www.ncbi.nlm.nih.gov/pubmed/34773678
http://dx.doi.org/10.1002/epi4.12560
work_keys_str_mv AT takahashiyukitoshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT otaakiko differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT tohyamajun differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT kirinotomoko differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT fujiwarayumi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT ikedachizuru differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT tanakashigeki differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT takahashijyunya differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT shinokitoshihiko differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT shiragahiroshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT inouetakushi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT fujitahiroshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT bonnomotoki differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT nagaomasayoshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures
AT kanekohideo differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures